SMAD3 and metabolic dysfunction-associated steatotic liver disease: Mechanistically, we uncovered that Smad3 targeted peroxisome proliferator-activated receptor delta (PPARδ) to induce dyslipidemia and NAFLD in <i>db/db</i> mice, which was improved by genetically deleting and pharmacologically inhibiting Smad3.